3,5-dimethyl-4-(3'-isopropyl-4'-O-methoxymethylbenzyl)-O-triisopropylsilylphenol | 328236-46-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3,5-dimethyl-4-(3'-isopropyl-4'-O-methoxymethylbenzyl)-O-triisopropylsilylphenol
• 英文别名: 2,6-dimethyl-(4'-methoxymethoxy-3'-iso-propylbenzyl)-4-triisopropylsilyloxybenzene；Triisopropyl(4-(3-isopropyl-4-(methoxymethoxy)benzyl)-3,5-dimethylphenoxy)silane；[4-[[4-(methoxymethoxy)-3-propan-2-ylphenyl]methyl]-3,5-dimethylphenoxy]-tri(propan-2-yl)silane
• CAS: 328236-46-0
• 化学式: C₂₉H₄₆O₃Si
• 分子量: 470.768
• InChiKey: JGEDAKSOKVIKAI-UHFFFAOYSA-N

物化性质

• 沸点：
  525.5±50.0 °C(Predicted)
• 密度：
  0.958±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  8.55
• 重原子数：
  33
• 可旋转键数：
  11
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  27.7
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3,5-dimethyl-4-(3'-isopropyl-4'-O-methoxymethylbenzyl)-O-triisopropylsilylphenol 在 氯化亚砜 、 palladium 10% on activated carbon 、 四丁基氟化铵 、 氢气 、 四氯化钛 、 caesium carbonate 、 三乙胺 、 N,N-二甲基甲酰胺 、 三氟乙酸 作用下， 以 四氢呋喃 、 二氯甲烷 、 乙酸乙酯 、 乙腈 为溶剂， 反应 2.5h， 生成 (2R,4S)-4-(3-chlorophenyl)-2-[(4-{[4-hydroxy-3-(propan-2-yl)phenyl]methyl}-3,5-dimethylphenoxy)methyl]-1,3,2λ5-dioxaphosphinan-2-one
  参考文献：
  名称：

  PREPARATION METHOD OF A CYCLIC PHOSPHONATE COMPOUND

  摘要：

  描述了一种制备公式I的环磷酸酯化合物的方法。该方法显著提高了具有所需构型的化合物的立体选择性。

  公开号：

  US20210277039A1
• 作为产物：
  描述：

  4-溴-2-异丙基苯酚 在 palladium on activated charcoal 、 氢气 、 magnesium 、 溶剂黄146 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 乙醇 、 二氯甲烷 为溶剂， 反应 32.0h， 生成 3,5-dimethyl-4-(3'-isopropyl-4'-O-methoxymethylbenzyl)-O-triisopropylsilylphenol
  参考文献：
  名称：

  追逐 THR 拮抗剂 NH-3 难以捉摸的苯并呋喃杂质：合成、同位素标记和生物活性

  摘要：

  我们已经合成并确定了在 NH-3 合成过程中形成的一种长期怀疑但迄今为止未知的苯并呋喃副产物 (EBI) 的结构。了解其形成机制已启用同位素 (D) 标记。我们进一步开发了一种从 NH-3 中分离 EBI 的高效方法。有趣的是，EBI 被发现是一种非常有效的甲状腺激素受体 (THR) 激动剂，而 NH-3 是一种拮抗剂。在这个过程中，我们还实现了 NH-3 合成的显着改进。

  DOI：

  10.1021/acs.joc.5b02665

文献信息

• Novel Phosphinic Acid-Containing Thyromimetics
  申请人：Erion Mark D.

  公开号：US20090028925A1

  公开（公告）日：2009-01-29

  The present invention relates to compounds of phosphonic acid-containing T3 mimetics and monoesters thereof, stereoisomers, pharmaceutically acceptable salts, co-crystals, and prodrugs thereof and pharmaceutically acceptable salts and co-crystals of the prodrugs, as well as their preparation and uses for preventing and/or treating metabolic diseases such as obesity, NASH, hypercholesterolemia and hyperlipidemia, as well as associated conditions such as atherosclerosis, coronary heart disease, impaired glucose tolerance, metabolic syndrome x and diabetes.

  本发明涉及含有磷酸基T3拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟
• Hammett Analysis of Selective Thyroid Hormone Receptor Modulators Reveals Structural and Electronic Requirements for Hormone Antagonists
  作者：Ngoc-Ha Nguyen、James W. Apriletti、John D. Baxter、Thomas S. Scanlan

  DOI：10.1021/ja0440093

  日期：2005.4.1

  Selective thyroid hormone modulators that function as isoform-selective agonists or antagonists of the thyroid hormone receptors (TRs) might be therapeutically useful in diseases associated with aberrant hormone signaling. The most potent thyroid hormone antagonist reported to date is NH-3. To explore the significance of the 5'-p-nitroaryl moiety of NH-3 and understand what chemical features are important

  作为甲状腺激素受体 (TR) 的异构体选择性激动剂或拮抗剂的选择性甲状腺激素调节剂可能对与异常激素信号传导相关的疾病有治疗作用。迄今为止报道的最有效的甲状腺激素拮抗剂是 NH-3。为了探索 NH-3 的 5'-对硝基芳基部分的重要性并了解哪些化学特征对赋予拮抗作用很重要，我们试图扩展 5'-苯基乙炔基 GC-1 衍生物类的构效关系数据. 在此，我们描述了一种改进的合成路线，利用钯催化化学有效地获得一系列具有不同尺寸和电子特性的 5'-苯基乙炔基化合物。我们准备并测试了 16 种类似物的 TR 结合和反式激活活性。在 5' 位置替换减少绑定亲和力，但保留 TRbeta 选择性。在反式激活试验中，类似物显示出一系列激动剂、拮抗剂和混合激动剂/拮抗剂活性，这些活性与西格玛取代基值和 TR 调制之间的哈米特分析中的电子特征相关。类似物 NH-5、NH-7、NH-9、NH-11 和 NH-23 显示出完整的拮抗剂活性，但与
• [EN] NOVEL PHOSPHORUS-CONTAINING THYROMIMETICS<br/>[FR] NOUVELLES SUBSTANCES THYROMIMETIQUES CONTENANT DU PHOSPHORE
  申请人：METABASIS THERAPEUTICS INC

  公开号：WO2005051298A3

  公开（公告）日：2005-08-11
• Synthesis and Biological Evaluation of a Series of Liver-Selective Phosphonic Acid Thyroid Hormone Receptor Agonists and Their Prodrugs
  作者：Serge H. Boyer、Hongjian Jiang、Jason D. Jacintho、Mali Venkat Reddy、Haiqing Li、Wenyu Li、Jennifer L. Godwin、William G. Schulz、Edward E. Cable、Jinzhao Hou、Rongrong Wu、James M. Fujitaki、Scott J. Hecker、Mark D. Erion

  DOI：10.1021/jm800824d

  日期：2008.11.27

  Phosphonic acid (PA) thyroid hormone receptor (TR) agonists were synthesized to exploit the poor distribution of PA-based drugs to extrahepatic tissues and thereby to improve the therapeutic index. Nine PAs showed excellent TR binding affinities (TR beta(1), K-i < 10 nM), and most of them demonstrated significant cholesterol lowering effects in a cholesterol-fed rat (CFR) model. Unlike the corresponding carboxylic acid analogue and T-3, PA 22c demonstrated liver-selective effects by inducing maximal mitochondrial glycerol-3-phosphate dehydrogenase activity in rat liver while having no effect in the heart. Because of the low oral bioavailability of PA 22c, a series of prodrugs was synthesized and screened for oral efficacy in the CFR assay. The liver-activated cyclic 1-(3-chlorophenyl)-1,3-propanyl prodrug (MB07811) showed potent lipid lowering activity in the CFR (ED50 0.4 mg/kg, po) and good oral bioavailability (40%, rat) and was selected for development for the treatment of hypercholesterolemia.
• Rational Design and Synthesis of a Novel Thyroid Hormone Antagonist That Blocks Coactivator Recruitment
  作者：Ngoc-Ha Nguyen、James W. Apriletti、Suzana T. Cunha Lima、Paul Webb、John D. Baxter、Thomas S. Scanlan

  DOI：10.1021/jm0201013

  日期：2002.7.1

  Recent efforts have focused on the design and synthesis of thyroid hormone (T-3) antagonists as potential therapeutic agents and chemical probes to understand hormone-signaling pathways. We previously reported the development of novel first-generation T-3 antagonists DIBRT, HY-4, and GC-14 using the "extension hypothesis" as a general guideline in hormone antagonist design.(1-3) These compounds contain extensions at the 5'-position (DIBRT, GC-14) of the outer thyronine ring or from the bridging carbon (HY-4). All of these compounds have only a modest affinity and potency for the thyroid hormone receptor (TR) that limits studies of their antagonistic actions. Here, we report the design and synthesis of a novel series of 5'-phenylethynyl derivatives sharing the GC-1 halogen-free thyronine scaffold.(4) One compound (NH-3) is a T-3 antagonist with negligible TR agonist activity and improved TR binding affinity and potency that allow for further characterization of its observed activity. One mechanism for antagonism appears to be the ability of NH-3 to block TR-coactivator interactions. NH-3 will be a useful pharmacological tool for further study of T-3 signaling and TR function.